A Phase I, Open Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma
This study is a Multiple centers, open design aimed at evaluating the safety,efficacy and Production feasibility of Autologous Tumor-Infiltrating Lymphocyte (GTE-001 injection ) for treatment of patients with Advanced lung adenocarcinoma,And evaluate potential biomarkers related to GTE-001 activity.
• 1\. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• 2\. Age ≥18 years old;
• 3\. Advanced lung adenocarcinoma that progresses after recurrence or first-line chemotherapy；
• 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• 5\. Expected survival time of ≥ 3 months;
• 6\. Good function of vital organs;
• 7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.